Author

PH O'Donnell

Observed name: P.H. O'Donnell

Institution: University of Chicago

Observed institution: University of Chicago

OpenAlex ID: A5085783126

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

2017 · JA Luzum, RE Pakyz, et al. · Clinical Pharmacology & Therapeutics · 138

Pharmacogenomics‐Based Point‐of‐Care Clinical Decision Support Significantly Alters Drug Prescribing

2017 · PH O'Donnell, N Wadhwa, et al. · Clinical Pharmacology & Therapeutics · 93

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program

2016 · RP McKillip, BA Borden, et al. · Clinical Pharmacology & Therapeutics · 32

Disease–drug database for pharmacogenomic‐based prescribing

2016 · S Hussain, BB Kenigsberg, et al. · Clinical Pharmacology & Therapeutics · 19

The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone

2016 · PH O'Donnell, K Danahey, et al. · Clinical Pharmacology & Therapeutics · 16

EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma

2026 · J.E. Rosenberg, P.H. O'Donnell, et al. · ESMO Open · 1

A0875 KEYNOTE-905 study of neoadjuvant and adjuvant (neoadj-adj) Enfortumab Vedotin (EV) plus pembrolizumab (pembro) in participants with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Assessment of surgical outcomes

2026 · N. Shore, S. Rausch, et al. · European Urology

Works count: 7

Citation count: 299

H-index: 5

I10-index: 5